Released May 9, 2013, after the close
10-Q filed May 9, 2013, 39 days after period end · 0001144204-13-027499
Q1 2013 · 10-Q
Revenue$3.57M$3.57M −7.6% vs Q1 2012+204.4% vs Q4 2012
Net Income-$4.32M-$4.32M N/M vs Q1 2012N/M vs Q4 2012
EPS Diluted$0.05$0.05 −28.6% vs Q1 2012no prior Q4 2012 on file
Gross Profit$2,997,000+24.5%
Operating Income-$4,429,000N/M
Operating Cash Flow-$9,586,000N/M
Free Cash Flowderived-$10,228,000N/M
Margins · derived
Gross margin84.0%+21.6 pt vs Q1 2012
Operating margin-124.1%+33.0 pt vs Q1 2012
Net margin-121.1%+31.8 pt vs Q1 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|
| Revenue | $3.57M | $3.86M | — |
| Net Income | -$4.32M | -$5.90M | -$5.05M |
| EPS Diluted | $0.05 | $0.07 | $0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR